About 300 reports

They provide rapid pain relief but do not slow disease progression or treat major inflammation.

  • Targeted Therapy
  • Asia
  • World
  • Market Size
  • Galapagos NV

The inhibition of COX can provide relief from symptoms of inflammation and pain.

  • Targeted Therapy
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Mylan Inc.

Many of these are long-acting drugs that do not provide immediate pain relief but instead take effect over the course of a number of weeks or months and are administered regularly over a long-term period as a maintenance therapy.

  • Targeted Therapy
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

Prostate cancer: palliative care and pain relief.

  • Targeted Therapy
  • World
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Pfizer Inc.

ANT A HIGH-PRICE TULA RA IS BOTH AN INHIBITOR OF IL-## ADN RE, ONLY LISMTX, US KEY OPINION LEADER ##. ##. ##. ## Dosing and Formulation US KEY OPINION LEADER ##. ##. ##. ## Safety Pipeline Assessment OTHER GENERIC SYSTEMIC THERAPIES, AND ADD-ON PAIN RELIEF MEDICINE.

  • Targeted Therapy
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novartis AG

Radiotherapy (RT) is also used to provide effective bone pain relief, with a Cochrane meta-analysis of ## trials finding that ##% of patients can expect to gain a ##% reduction in pain (McQuay et al., 2000).

  • Targeted Therapy
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • Europe
  • Demand
  • Market Size
  • Novartis AG
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

THE PURPOSE OF THE STUDY WAS TO TEST THE EFFICACY AND SAFETY OF TWO DOSES LEVELS OF RN## VERSUS PLACEBO FOR THE RELIEF OF PAIN CAUSED BY POST-HERPETIC NEURALGIA (PHN).

  • Chronic Pain
  • Targeted Therapy
  • United States
  • World
  • Pfizer Inc.
  • CANAKINUMAB - DRUG PROFILE

The goal of treatment is to reduce pain and prevent serious problems. "

  • Targeted Therapy
  • Turkey
  • United States
  • World
  • Product Initiative
  • canakinumab - Drug Profile

The most common AEs were abdominal pain and nasopharyngitis.

  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Novartis AG

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Bristol-Myers Squibb Company

The secondary outcome measures of the study were tumor response assessed via CT scan using RECIST and effects on pain relief using a patient self-assessment pain scale.

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Amgen Inc.

There was a trend towards improvement in pain that was not statistically significant.

  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.

The difference in pain response between the arms was not statistically significant.

  • Lung Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Hospital
  • Targeted Therapy
  • United States
  • Product Initiative
  • Merrimack Pharmaceuticals, Inc.

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative
  • MedImmune, LLC

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • PIPELINE BY GIGAGEN INC, H1 2018

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

The third patient had stable disease on bone scan. ##-Nov-2011 Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Exelixis, Inc.

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Immune Design
  • patients (83.7%) experienced at least a 30% improvement in symptoms vs. 9.8% for placebo (p
  • CANAKINUMAB - DRUG PROFILE

The most common AEs were abdominal pain and nasopharyngitis.

  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.